Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Tipo de documento
Ano de publicação
Intervalo de ano de publicação
1.
J Infect Dis ; 229(6): 1796-1802, 2024 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-38206187

RESUMO

BACKGROUND: Limited data are available regarding the susceptibility of the reverse transcriptase V106 polymorphism to doravirine. METHODS: Doravirine susceptibility was measured in site-directed mutants (SDMs) containing V106I, V106A, V106M, and Y188L mutations in subtype B (NL4-3, HXB2) and CRF02_AG background and in recombinant viruses with RT harboring V106I alone derived from 50 people with HIV. RESULTS: HIV-1 B subtype was detected in 1523 of 2705 cases. Prevalence of V106I was 3.2% in B and 2.5% in non-B subtypes, and was higher in subtype F (8.1%) and D (14.3%). Fold-changes (FC) in susceptibility for SDMs were below doravirine biological cutoff (3.0) for V106I, but not for V106A, V106M, and Y188L. Clinically derived viruses tested included 22 B (median FC, 1.2; interquartile range [IQR], 0.9-1.6) and 28 non-B subtypes (median FC, 1.8; IQR, 0.9-3.0). Nine (18%) viruses showed FC values equal or higher than the doravirine biological FC cutoff. CONCLUSIONS: The prevalence of the HIV-1 RT V106I polymorphism in MeditRes HIV consortium remains low, but significantly more prevalent in subtypes D and F. V106I minimally decreased the susceptibility to doravirine in SDMs and most clinical isolates. Reduced susceptibility seems to occur at increased frequency in subtype F1; however, the clinical impact remains to be investigated. CLINICAL TRIALS REGISTRATION: NCT04894357.


Assuntos
Fármacos Anti-HIV , Farmacorresistência Viral , Infecções por HIV , Transcriptase Reversa do HIV , HIV-1 , Piridonas , Triazóis , Humanos , HIV-1/genética , HIV-1/efeitos dos fármacos , HIV-1/classificação , HIV-1/enzimologia , Transcriptase Reversa do HIV/genética , Infecções por HIV/virologia , Infecções por HIV/epidemiologia , Piridonas/farmacologia , Farmacorresistência Viral/genética , Fármacos Anti-HIV/farmacologia , Triazóis/farmacologia , Polimorfismo Genético , Prevalência , Masculino , Feminino , Inibidores da Transcriptase Reversa/farmacologia , Adulto , Genótipo , Fenótipo , Pessoa de Meia-Idade
2.
Artigo em Inglês | MEDLINE | ID: mdl-39028674

RESUMO

BACKGROUND: Transmitted drug resistance (TDR) is still a critical aspect for the management of individuals living with HIV-1. Thus, its evaluation is crucial to optimize HIV care. METHODS: Overall, 2386 HIV-1 protease/reverse transcriptase and 1831 integrase sequences from drug-naïve individuals diagnosed in north and central Italy between 2015 and 2021 were analysed. TDR was evaluated over time. Phylogeny was generated by maximum likelihood. Factors associated with TDR were evaluated by logistic regression. RESULTS: Individuals were mainly male (79.1%) and Italian (56.2%), with a median (IQR) age of 38 (30-48). Non-B infected individuals accounted for 44.6% (N = 1065) of the overall population and increased over time (2015-2021, from 42.1% to 51.0%, P = 0.002). TDR prevalence to any class was 8.0% (B subtype 9.5% versus non-B subtypes 6.1%, P = 0.002) and remained almost constant over time. Overall, 300 transmission clusters (TCs) involving 1155 (48.4%) individuals were identified, with a similar proportion in B and non-infected individuals (49.7% versus 46.8%, P = 0.148). A similar prevalence of TDR among individuals in TCs and those out of TCs was found (8.2% versus 7.8%, P = 0.707).By multivariable analysis, subtypes A, F, and CFR02_AG were negatively associated with TDR. No other factors, including being part of TCs, were significantly associated with TDR. CONCLUSIONS: Between 2015 and 2021, TDR prevalence in Italy was 8% and remained almost stable over time. Resistant strains were found circulating regardless of being in TCs, but less likely in non-B subtypes. These results highlight the importance of a continuous surveillance of newly diagnosed individuals for evidence of TDR to inform clinical practice.

3.
J Med Virol ; 96(5): e29642, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38708812

RESUMO

Molnupiravir, an oral direct-acting antiviral effective in vitro against SARS-CoV-2, has been largely employed during the COVID-19 pandemic, since December 2021. After marketing and widespread usage, a progressive increase in SARS-CoV-2 lineages characterized by a higher transition/transversion ratio, a characteristic signature of molnupiravir action, appeared in the Global Initiative on Sharing All Influenza Data (GISAID) and International Nucleotide Sequence Database Collaboration (INSDC) databases. Here, we assessed the drug effects by SARS-CoV-2 whole-genome sequencing on 38 molnupiravir-treated persistently positive COVID-19 outpatients tested before and after treatment. Seventeen tixagevimab/cilgavimab-treated outpatients served as controls. Mutational analyses confirmed that SARS-CoV-2 exhibits an increased transition/transversion ratio seven days after initiation of molnupiravir. Moreover we observed an increased G->A ratio compared to controls, which was not related to apolipoprotein B mRNAediting enzyme, catalytic polypeptide-like (APOBEC) activity. In addition, we demonstrated for the first time an increased diversity and complexity of the viral quasispecies.


Assuntos
Antivirais , Tratamento Farmacológico da COVID-19 , Citidina/análogos & derivados , Genoma Viral , Hidroxilaminas , SARS-CoV-2 , Humanos , SARS-CoV-2/genética , SARS-CoV-2/efeitos dos fármacos , Antivirais/uso terapêutico , Antivirais/farmacologia , Hidroxilaminas/farmacologia , Hidroxilaminas/uso terapêutico , Masculino , Feminino , Estudos de Casos e Controles , Pessoa de Meia-Idade , Citidina/uso terapêutico , Citidina/farmacologia , Idoso , Adulto , Sequenciamento Completo do Genoma , Variação Genética , Uridina/farmacologia , COVID-19/virologia , Mutação
4.
Viruses ; 16(7)2024 Jun 24.
Artigo em Inglês | MEDLINE | ID: mdl-39066176

RESUMO

Enteroviruses (EVs) are ubiquitous viruses that circulate worldwide, causing sporadic or epidemic infections, typically during the summer and fall. They cause a broad spectrum of illnesses, ranging from an unspecified febrile clinical presentation to a severe illness. EVs are recognized to be the most frequent etiological agents of aseptic meningitis in children. However, as the infection is usually mild and self-limiting, it remains underestimated, and the epidemiology of EVs is poorly understood. To date, no vaccine or effective therapy for all types of enteroviruses is available, and EVs constitute a public health concern. Here, we investigated the molecular epidemiology of EV strains circulating in the Lazio region over a 10-year time span (2012-2023) by using a sequence-typing approach and phylogenetic analysis. The epidemiological trend of EV infection has undergone changes during the SARS-CoV-2 pandemic (2020-2021), which resulted in a modification in terms of the number of diagnosed cases and seasonality. From 2022, the circulation of EVs showed a behavior typical of the pre-pandemic period, although changes in predominantly circulating strains have been noted. Both epidemic and sporadic circulation events have been characterized in the Lazio region. Further analyses are needed to better characterize any strain with higher potential pathogenic power and to identify possible recombinant strains.


Assuntos
Infecções por Enterovirus , Enterovirus , Genótipo , Epidemiologia Molecular , Filogenia , Humanos , Infecções por Enterovirus/virologia , Infecções por Enterovirus/epidemiologia , Enterovirus/genética , Enterovirus/classificação , Enterovirus/isolamento & purificação , Estações do Ano , COVID-19/epidemiologia , COVID-19/virologia , SARS-CoV-2/genética , SARS-CoV-2/classificação , Criança
5.
Viruses ; 16(7)2024 Jun 27.
Artigo em Inglês | MEDLINE | ID: mdl-39066203

RESUMO

Despite emerging evidence indicating that molecular SARS-CoV-2 tests performed on saliva have diagnostic sensitivity and specificity comparable to those observed with nasopharyngeal swabs (NPSs), most in vivo follow-up studies on the efficacy of drugs against SARS-CoV-2 have been performed on NPSs, not considering saliva as a possible alternative matrix. For this reason, in this study, we used, in parallel, saliva and NPS samples for the detection of SARS-CoV-2 by real-time RT-PCR in patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab as a treatment against SARS-CoV-2. Our results showed a good correlation between the NPS and saliva samples for each drug; moreover, comparable changes in the cycle threshold (Ct) levels in saliva and NPSs were observed both 7 days and 30 days after treatment, thus confirming that the saliva represents a good matrix for in vivo follow-up studies verifying the effectiveness of treatments against SARS-CoV-2.


Assuntos
Tratamento Farmacológico da COVID-19 , COVID-19 , Nasofaringe , Ritonavir , SARS-CoV-2 , Saliva , Sensibilidade e Especificidade , Humanos , Saliva/virologia , SARS-CoV-2/isolamento & purificação , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/genética , COVID-19/diagnóstico , COVID-19/virologia , Ritonavir/uso terapêutico , Nasofaringe/virologia , Seguimentos , Antivirais/uso terapêutico , Resultado do Tratamento , Anticorpos Monoclonais Humanizados/uso terapêutico , Combinação de Medicamentos , Lopinavir/uso terapêutico , Feminino , Masculino , Teste de Ácido Nucleico para COVID-19/métodos , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA